The AI drug revolution is real but the hype around it isn’t

AI is transforming drug discovery, but the hype around its potential to eliminate diseases quickly is misleading. While tech leaders predict dramatic advancements, the complex nature of biology resists simple solutions. Despite high-profile failures and restructuring in companies like BenevolentAI, AI is indeed making strides in the preclinical phase, significantly reducing the time to identify viable drug candidates from years to just months. The real revolution lies in leveraging AI's capabilities effectively, rather than expecting overnight miracles.